Allogene PT receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Allogene Therapeutics Inc (ALLO)
NASDAQ
Symbol | Exchange | Currency |
|---|
16.74
-0.51(-2.96%)
- Volume:444,437
- Day's Range:16.72 - 17.39
- 52 wk Range:6.43 - 27.86
ALLO Overview
- Prev. Close
- 17.25
- Day's Range
- 16.72-17.39
- Revenue
- 247K
- Open
- 17.13
- 52 wk Range
- 6.43-27.86
- EPS
- -2.19
- Volume
- 444,437
- Market Cap
- 2.41B
- Dividend (Yield)
- N/A(N/A)
- Average Vol. (3m)
- 2,019,595
- P/E Ratio
- -7.86
- Beta
- 0.548
- 1-Year Change
- -19.54%
- Shares Outstanding
- 143,806,825
- Next Earnings Date
- Nov 09, 2022
What is your sentiment on Allogene Therapeutics?
or
Vote to see community's results!
Allogene Therapeutics Inc News
- Allogene receives Investment Bank Analyst Rating Update
- ByInvesting.com-
- Allogene Therapeutics, Inc. Tops Q2 EPS by 9c
- ByInvesting.com-
Allogene Therapeutics, Inc. (NASDAQ:ALLO) reported Q2 EPS of ($0.52), $0.09 better than the analyst estimate of ($0.61). Revenue for the quarter came in at $86 thousand versus the...
Allogene Therapeutics Inc Analysis
- Want To Invest In Founder-Led Companies Exclusively? There's An ETF For That
Businesses led by their founders receive significant attention on Wall Street and in academia. For instance, according to research by Bain & Co. published in Harvard Business...
- Gilead's (GILD) Kite Announces Positive Data on Yescarta
Gilead Sciences’ GILD Kite announced positive top-line results from the primary analysis of the global phase III multicenter study, ZUMA-7.ZUMA-7 evaluated a one-time...
- Why You Shouldn't Bet Against Allogene Therapeutics (ALLO) Stock
One stock that might be an intriguing choice for investors right now is Allogene Therapeutics, Inc. (NASDAQ:ALLO) . This is because this security in the Medical - Biomedical and...
Allogene Therapeutics Inc Company Profile
Allogene Therapeutics Inc Company Profile
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Sell | Neutral | Strong Buy | Neutral |
| Technical Indicators | Strong Sell | Strong Sell | Sell | Strong Buy | Sell |
| Summary | Strong Sell | Strong Sell | Neutral | Strong Buy | Neutral |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.12 | 8.13 | 7.85 | -0.25 | -2.98% | 3.59M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 31.80 | 31.82 | 30.71 | -0.95 | -2.90% | 4.40M | NYSE | |||
| 1.1685 | 1.19 | 1.15 | -0.0415 | -3.43% | 1.71M | NYSE | |||
| 1.075 | 1.09 | 1.05 | -0.0250 | -2.27% | 80.36K | NYSE | |||
| 45.40 | 45.49 | 44.78 | -0.86 | -1.86% | 1.16M | NYSE | |||
| 3.525 | 3.55 | 3.47 | -0.075 | -2.08% | 7.76M | NYSE | |||
| 20.30 | 20.52 | 19.80 | +0.18 | +0.89% | 693.30K | NASDAQ | |||
| 7.46 | 7.54 | 6.73 | +0.590 | +8.59% | 4.30M | NYSE | |||
| 14.33 | 15.06 | 13.37 | +1.38 | +10.66% | 77.04M | NASDAQ | |||
| 49.79 | 49.85 | 47.44 | -1.10 | -2.17% | 1.48M | NYSE | |||
| 0.78 | 0.79 | 0.776 | -0.010 | -1.27% | 5.42K | NASDAQ | |||
| 15.24 | 15.30 | 15.00 | +0.02 | +0.13% | 1.57M | OTC Markets | |||
| 0.0006 | 0.0006 | 0.0006 | 0.00000 | 0.00% | 0.00 | OTC Markets | |||
| 58.50 | 65.70 | 26.90 | +31.47 | +116.43% | 379.46K | NASDAQ |
- Oct 14, 2021, 19:30Bought it recently. Planning to hold until $26 good idea?
- Oct 14, 2021, 23:17There is still a gap to fill imo at 15,96
- Oct 15, 2021, 21:21What do you mean? (sorry i am a noob)
- Oct 16, 2021, 10:58Alpha RomeoA gap on a chart is considered to be filled when the price action moves back through the open gap area where transactions were missing. Check the 15,96 level on the chart.
- Oct 14, 2021, 19:23SOLD #ALLO @ 14.51000000
- Oct 13, 2021, 23:01Nice one today!
- Oct 13, 2021, 23:00This is running great
- Oct 14, 2021, 19:19cashed out at 17,22
- Oct 11, 2021, 18:30buy buy buy
- Oct 11, 2021, 18:10getting my 🚀🚀🚀🚀🚀🚀🚀🌋🙀
- Oct 11, 2021, 18:09at this price is Christmas
- Oct 08, 2021, 17:41Epic fall!
- Jan 27, 2021, 22:13I mean yes
- Dec 11, 2020, 23:20no comments! weird! dont you think this is a promising stock?